Evidence map›Paper›PMID 16465602›Full record

ArticleLung

Mechanism of endothelin-1 activation of MAP kinases in neonatal pulmonary vascular smooth muscle.

Scott A Barman, Mario B Marrero

Abstract read
PubMed Publisher
In one paragraph

Article in Lung. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Bosentan, an endothelin receptor antagonist, ameliorates collagen-induced arthritis: the role of TNF-α in the induction of endothelin system genes.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Scott A BarmanDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta, GA 30912, USA. sbarman@mail.mcg.edu
Mario B Marrero
Augusta University · US

Funding

PKC Signaling in cAMP-Induced Pulmonary VasodilationR01HL068026 · NHLBI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI BARMAN, SCOTT A · 2001 to 2010
$2.3M
The Angiotensin II-Induced JAK/STAT Pathway in Diabetes.R01HL058139 · NHLBI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MARRERO, MARIO BENEDICTO · 1999 to 2005
$1.3M
ANGIOTENSIN II &JAK-STAT PATHWAY IN VASCULAR GROWTHR29HL058139 · NHLBI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI MARRERO, MARIO B. · 1997 to 1998
–
NHLBI NIH HHS HL-58139NHLBI NIH HHS HL-68026
6 · The paper itself

Abstract

Mitogen-activated protein kinases (MAPKs) belong to the group of serine-threonine kinases that are rapidly activated in response to growth factor stimulation. In adult mammalian cells, the MAPK family includes extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2 or p44(mapk) and p42(mapk)), which translocate to the nucleus and integrate signals from second messengers leading to cellular proliferation or differentiation, but the specific role of MAPKs in neonatal pulmonary vascular smooth muscle is not well understood. Expression of p44(mapk) and p42(mapk) in primary cultured pulmonary vascular smooth muscle cells from neonatal (1-2 day old) rats was identified by Western immunoblot analysis and treatment with 10 nM endothelin-1 (ET-1), a potent vasoconstrictor with vascular mitogenic properties, induced cell proliferation, and phosphorylation of both p44(mapk) and p42(mapk). The protein kinase C (PKC) isozyme inhibitor (alpha, beta, gamma, delta, zeta) Go 6983, the ET(A) receptor antagonist BQ 123, and the MAPK kinase inhibitor PD98059 blocked the cell proliferation response to ET-1. Also, BQ 123, Go 6983, and PKC inhibitor 20-28 (Myr-N-FARKGAL-RQ-NH2-PKCalpha antagonist) inhibited ET-1-induced phosphorylation of both p44(mapk) and p42(mapk). In contrast, the reactive oxygen species (ROS) inhibitor diphenylene iodonium (DPI), the PKCdelta inhibitor rottlerin, and the ET(B) receptor antagonist BQ 788 did not block ET-1-induced phosphorylation of MAPKs. Collectively, these data demonstrate the expression and phosphorylation of MAPKs by ET-1 and suggests that MAPK activation and cell proliferation by ET-1 occurs via ET(A) receptor stimulation and specific PKC isozyme activation in rat neonatal pulmonary vascular smooth muscle.

Indexed as

AcetophenonesAnimalsAnimals, NewbornBenzopyransBlotting, WesternEndothelin-1Enzyme InhibitorsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Mitogen-Activated Protein KinasesMuscle, Smooth, VascularPhosphorylationProtein Kinase CRatsAcetophenonesBenzopyransEndothelin-1Enzyme InhibitorsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Mitogen-Activated Protein KinasesProtein Kinase Crottlerin

Identifiers

PMID16465602
OpenAlexW2038147892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.